Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | breast cancer 1, early onset | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Toxoplasma gondii | poly(ADP-ribose) polymerase catalytic domain-containing protein | 0.0012 | 0 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 1 | 1 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Plasmodium vivax | replication factor C subunit 1, putative | 0.0012 | 0 | 0.5 |
Chlamydia trachomatis | DNA ligase | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0 | 0.5 |
Trypanosoma cruzi | FHA domain containing protein, putative | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Trypanosoma brucei | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | NAD-dependent DNA ligase, Lig | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 1 | 1 |
Mycobacterium leprae | PROBABLE DNA LIGASE [NAD DEPENDENT] LIGA (POLYDEOXYRIBONUCLEOTIDE SYNTHASE [NAD+]) | 0.0012 | 0 | 0.5 |
Mycobacterium ulcerans | NAD-dependent DNA ligase LigA | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 1 | 1 |
Entamoeba histolytica | Activator 1 140 kDa subunit, putative | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 1 | 1 |
Toxoplasma gondii | ATPase, AAA family protein | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | replication factor C large subunit, putative | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 1 | 1 |
Treponema pallidum | DNA ligase (lig) | 0.0012 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0012 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0 | 0.5 |
Plasmodium falciparum | replication factor C subunit 1, putative | 0.0012 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 1 | 1 |
Giardia lamblia | Replication factor C, subunit 1 | 0.0012 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 10 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.